SpringerLink
Log in

The acute effects of intravenous nisoldipine on left ventricular function 24 to 72 hours after uncomplicated acute myocardial infarction

  • Calcium Antagonist
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

The acute effects on left ventricular function of nisoldipine were studied in six patients 56±12 hours (range 44 to 72 hours) after the onset of uncomplicated acute myocardial infarction. Nisoldipine was administered as a 4.5 μg/kg intravenous bolus over 3 minutes followed by an infusion of 0.2 μg/kg during 60 minutes. Radionuclide angiography and two-dimensional echocardiography were performed before and during infusien with nisoldipine. The left ventricular ejection fraction increased significantly from 38%±10% to 49%±10% (P=0.028) during nisoldipine infusion. Regional wall motion index was determined both by radionuclide and by two-dimensional echocardiography and showed a significant change during nisoldipine infusion from 1.9±0.3 to 1.5±0.3 (p=0.028, radionuclide angiography) and from 0.7±0.2 to 0.3±0.2 (p=0.043, two dimensional echocardiography). Heart rate increased significantly from 78±12 min-1 to 92±13 min-1 (p=0.028), but mean double product did not change significantly during nisoldipine infusion. It is concluded that nisoldipine significantly improves global and regional left ventricular function in patients shortly after acute myocardial infarction. This beneficial effect may, however, be partially offset by an increase in heart rate. Since mean double product did not change, it is suggested that nisoldipine may improve coronary blood flow in patients with acute myocardial infarction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kazda S, Garthoff B, Meyer H, et al. Pharmacology of a new calcium antagonistic compound, isobutyl methyl 1,4-dihydro-2,6 dimethyl-4-(2-nitrophenyl)-3,5-pyridinecarboxylate (nisoldipine, BAY K 5552). drug Res 1980; 30:2144–2162.

    Google Scholar 

  2. Warltier DC, Meils CM, Gross GJ, Brooks HL. Blood flow in normal and acutely ischemic myocardium after verapamil, diltiazem, and nisoldipine (BAY K 5552), a new dihydropyridine calcium antagonist. J Pharmacol Exp Ther 1981; 218:296–301.

    Google Scholar 

  3. Maxwell GM, Crompton S, Renics V. Effect of nisoldipine upon the general and coronary hemodynamics of the anaesthetized dog. J Cardiovasc Pharmacol 1982; 4:393–399.

    Google Scholar 

  4. Warltier D, Zyvoloski M, et al. Comparative actions of dihydropyridine slow channel blocking agents in conscious dogs: systemic and coronary hemodynamics with and without combined beta-adrenergic blockade. J Pharmacol Exp Ther 1984; 230:367–375.

    Google Scholar 

  5. Lathrop DA, Valle-Aguilera JR, Milard RW, et al. Comparative electrophysiologic and coronary hemodynamic effects of diltiazem, nisoldipine and verapamil on myocardial tissue. Am J Cardiol 1982; 49:613–620.

    Google Scholar 

  6. Klein HH, Nordbeck H, Kreuzer H. Effect of the calcium antagonist nisoldipine on electrophysiologic parameters in the human. Z Kardiol 1983; 72:180–182.

    Google Scholar 

  7. Serruys PW, Suryapranata H, Planellas J, et al. Acute effects of intravenous nisoldipine on left ventricular function and coronary hemodynamics. Am J Cardiol 1985; 56:140–146.

    Google Scholar 

  8. Soward AL, de Feyter PJ, Hugenholtz PG, Serruys PW. Coronary and systemic hemodynamic effects of intravenous nisoldipine. Am J Cardiol 1986; 58:1199–1203.

    Google Scholar 

  9. Soward AL, de Feyter PJ, Hugenholtz PG, Serruys PW. Maintenance of increased coronary blood flow in excess of demand by nisoldipine administration as an intravenous infusion. Am J Cardiol 1986; 58:1204–1208.

    Google Scholar 

  10. Nienaber CA, Spielmann RP, Aschenberg W, et al. Comparison of the acute hemodynamic response to intravenous nisoldipine (BAY K 5552) and intravenous nifedipine for left ventricular dysfunction secondary to myocardial infarction. Am J Cardiol 1987; 60:836–841.

    Google Scholar 

  11. Kimchi A, Ellrodt G, Charuzi Y, Shell W, Murata GH. Salutary hemodynamic and sustained clinical benefits of nisoldipine, a new calcium channel blocker, in patients with recurrent ischemia and severe heart failure. Am Heart J 1985; 110:496–498.

    Google Scholar 

  12. Silke B, Frais MA, Muller P, et al. Heamodynamic doseresponse effects of intravenous nisoldipine in coronary artery disease. Br J Clin Pharmacol 1985; 20:675–680.

    Google Scholar 

  13. Molhoek GP, Wesseling KH, Sellier JJ, et al. Evaluation of the Penaz servo-plethysmo-manometer for the continuous noninvasive measurement of finger blood pressure. Basic Res Cardiol 1984; 79:598–609.

    Google Scholar 

  14. Reiber JCH, Lie SP, Simoons ML, et al. Clinical validation of fully automated computation of ejection fraction from gated equilibrium blood-pool scintigrams. J Nucl Med 1983; 24:1099–1105.

    Google Scholar 

  15. Kan G, Visser CA, Meltzer RS, et al. Short and long term predictive value of admission wall motion score in acute myocardial infarction: A two-dimensional echocardiographic study of 345 patients. Br Heart J 1986; 56:422–427.

    Google Scholar 

  16. Hamm CW, Opie LH. Protection of infarcting myocardium by slow channel inhibitors. Circ Res 1983;52(Suppl 1):129–138.

    Google Scholar 

  17. Gordon GD, Mabin TA, Isaacs C, et al. Hemodynamic effects of sublingual nifedipine in acute myocardial infarction. Am J Cardiol 1984; 53:1228–1232.

    Google Scholar 

  18. Cantelli I, Pavesi PC, Nacarralla F, Bracchetti D. Comparison of acute hemodynamic effects of nifedipine and isosorbide dinitrate in patients with heart failure following acute myocardial infarction. Int J Cardiol 1981; 1:151–163.

    Google Scholar 

  19. Roberts R, Jaffe AS, Henry PB, Sobel BE. Nifedipine and acute myocardial infarction. Herz 1981; 6:90–97.

    Google Scholar 

  20. Sirnes PA, Overskied K, Pedersen TJ, et al. Evolution of infarct size during the early use of nifedipine in patients with acute myocardial infarction: The Norwegian Nifedipine Multicenter Trial. Circulation 1984; 70:638–644.

    Google Scholar 

  21. Muller JE, Tur ZG, Pearle DL, et al. Nifedipine and conventional therapy for unstable angina pectoris: A randomized, double-blind comparison. Circulation 1984; 69:728–739.

    Google Scholar 

  22. The Holland Interuniversity Nifedipine/metoprolol Trial (HINT) research group. Early treatment of unstable angina in the coronary care unit: A randomised, double blind, placebo controlled comparison of recurrent ischaemia in patients treated with nifedipine or metoprolol or both. Br Heart J 1986; 56:400–413.

    Google Scholar 

  23. The Danish Study Group on verapamil in myocardial infarction. Verapamil in myocardial infarction. Eur Heart J 1984; 5:516–528.

    Google Scholar 

  24. Gottlieb SO, Becker LC, Weiss JL, et al. Nifedipine in acute myocardial infarction: an assessment of left ventricular function, infarct size, and infarct expansion. Br Heart J 1988; 59:411–418.

    Google Scholar 

  25. The Israeli Sprint Study Group. Secondary prevention reinfarction Israeli nifedipine trial (SPRINT). A randomized intervention trial of nifedipine in patients with acute myocardial infarction. Eur Heart J 1988; 9:354–364.

    Google Scholar 

  26. Gibson RS, Young PM, Boden WE, Schlechtman K, et al. Prognostic significance and beneficial effect of diltiazem on the incidence of early recurrent ischemia after non-Q-wave myocardial infarction: Results from the Multicenter Diltiazem Reinfarction Study. Am J Cardiol 1987; 4:203–209.

    Google Scholar 

  27. Lewis BS, Shefer A, Merdler A, et al. Effect of the second-generation calcium channel blocker nisoldipine on left ventricular contractility in cardiac failure. Am Heart J 1988; 115:1238–1244.

    Google Scholar 

  28. Van der Wall EE, Kernkamp HJ, Simoons ML, et al. Influence of nifedipine on left ventricular perfusion and function in patients with unstable angina: Evaluation with radionuclide techniques. Eur J Nucl Med 1986; 11:428–433.

    Google Scholar 

  29. Drexler H, Truog AG, Zelis R, Flaim SF. Regional vascular and hemodynamic effects of orally administered nisoldipine in conscious rats. J Cardiovasc Pharmacol 1986; 8:151–155.

    Google Scholar 

  30. Rousseau MF, Vincent MF, Hoof F, et al. Effects of nicardipine and nisoldipine on myocardial metabolism, coronary blood flow and oxygen supply in angina pectoris. Am J Cardiol 1981; 47:163–173.

    Google Scholar 

  31. Kleinbloesem CH, van Brummelen P, Danhof M, et al. Rate of increase in the plasma concentration of nifedipine as a major determinant of its haemodynamic effects in human. Clin Pharmacol Ther 1987; 41:26–30.

    Google Scholar 

  32. Lopez LM, Rubin MR, Holland JP, Mehta SL. Improvements in exercise performance with nisoldipine, a new second-generation calcium blocker, in stable angina patients. Am Heart J 1985; 110:991–996.

    Google Scholar 

  33. Lam J, Chaitman BR, Crean P, et al. A dose-ranging placebo-controlled, double-blind trial of nisoldipine in effort angina: Duration and extent of antianginal effects. J Am Coll Cardiol 1985; 6:447–452.

    Google Scholar 

  34. Tumas J, Deth R, Kloner RA. Effects of nisoldipine, a new calcium antagonist, on myocardial infarct size and cardiac dynamics following acute myocardial infarction. J Cardiovasc Pharmacol 1985; 7:361–367.

    Google Scholar 

  35. Fagbemi O, Parratt JR. Suppression by orally-administered nifedipine, nisoldipine, and niludipine of early, life-threat-ening ventricular arrhythmias resulting from acute myocardial ischemia. Br J Pharmacol 1981; 74:12–14.

    Google Scholar 

  36. De Jong JW, Huizer T, Tijssen JGP. Energy conservation by nisoldipine in ischemic heart. Br J Pharmacol 1984; 83:943–949.

    Google Scholar 

  37. Mentley RK, Brezinski ME, Tse E, Lefer AM. Cardioprotective actions of nisoldipine in postreperfusion myocardial ischemia. Am Heart J 1988; 115:948–954.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology of the University Hospital Leiden, Leiden

    Ron C. de Nooijer, Ernst E. van der Wall, Volkert Manger Cats, Ge van Herpen, Arnoud van der Laarse & Albert V. G. Bruschke

  2. Department of Nuclear Medicine of the University Hospital Leiden, Leiden

    Jacobus A. K. Blokland & Jan W. Arndt

  3. Department of Cardiology of the Antonius Ziekenhuis, Nieuwegein, The Netherlands

    Wybren Jaarsma

Authors
  1. Ron C. de Nooijer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ernst E. van der Wall
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Volkert Manger Cats
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ge van Herpen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Arnoud van der Laarse
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jacobus A. K. Blokland
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wybren Jaarsma
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jan W. Arndt
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Albert V. G. Bruschke
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

de Nooijer, R.C., van der Wall, E.E., Cats, V.M. et al. The acute effects of intravenous nisoldipine on left ventricular function 24 to 72 hours after uncomplicated acute myocardial infarction. Cardiovasc Drug Ther 2, 673–678 (1988). https://doi.org/10.1007/BF00054208

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00054208

Key words

Search

Navigation